Summary: Neutralizing antibody (NAb) titer is a key biomarker of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but point-of-care methods for assessing NAb
SARS-CoV-2 infection and/or vaccination elicit a broad range of neutralizing antibody responses against the different variants of concern (VOC). We established a new variant-adapted surrogate neutrali
This file is also available at: https://github.com/jbloomlab/SARS-CoV-2-RBD_B.1.351/blob/main/experimental_data/results/rbd_depletion_neuts/RBD_depletion_NT50_b1351_haarvi.csv (CSV)
